M&A / Deals Biogen to acquire RayThera for up to $1bn Pharmaceutical Business ReviewThe deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones.NeuroscienceRead full story pharminent June 19, 2026 (Last updated: June 19, 2026) Pharmaceutical Business Review The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones. Neuroscience Read full story Post navigation Previous: FDA experts endorse Moderna’s mRNA seasonal flu shotNext: US launches probe of German ‘underpayment’ for medicines Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
